Keywords: topotarget, says, failed, aguvane, study, worthwhile, although

TopoTarget says failed Aguvane study was worthwhile

Article | 30 March 2009

Print This

Although Danish firm TopoTarget's Avugane gel (valproic acid) failed to reach significance in a Phase II trial comparing three doses ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in